{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:52:19Z","timestamp":1792803139730,"version":"4.5.0"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T00:00:00Z","timestamp":1608854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"US Department of Veterans Affairs Health Services Research & Development","award":["1I01HX002917-01A1"],"award-info":[{"award-number":["1I01HX002917-01A1"]}]},{"name":"Department of VA or the US government"},{"name":"US National Institute of Diabetes and Digestive and KidneyDiseases","award":["K23DK122131"],"award-info":[{"award-number":["K23DK122131"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,9,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Treatment with renin\u2013angiotensin system inhibitors (RASIs), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) is the standard of care for those with chronic kidney disease (CKD) and albuminuria. However, ACEI\/ARB treatment is often discontinued for various reasons. We investigated the association of ACEI\/ARB discontinuation with outcomes among US veterans with non-dialysis-dependent CKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective cohort study of patients in the Veterans Affairs healthcare system with non-dialysis-dependent CKD who subsequently were started on ACEI\/ARB therapy (new user design). Discontinuation events were defined as a gap in ACEI\/ARB therapy of \u226514\u2009days and were classified further based on duration (14\u201330, 31\u201360, 61\u201390, 91\u2013180 and &amp;gt;180\u2009days). This was treated as a time-varying risk factor in adjusted Cox proportional hazards models for the outcomes of death and incident end-stage kidney disease (ESKD), which also adjusted for relevant confounders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 141\u2009252 people with CKD and incident ACEI\/ARB use who met the inclusion criteria; these were followed for a mean 4.87\u2009years. There were 135\u2009356 discontinuation events, 68\u2009699 deaths and 6152 incident ESKD events. Discontinuation of ACEI\/ARB was associated with a higher risk of death [hazard ratio (HR) 2.3, 2.0, 1.99, 1.92 and 1.74 for those discontinued for 14\u201330, 31\u201360, 61\u201390, 91\u2013180 and &amp;gt;180\u2009days, respectively]. Similar associations were noted between ACEI and ARB discontinuation and ESKD (HR 1.64, 1.47, 1.54, 1.65 and 1.59 for those discontinued for 14\u201330, 31\u201360, 61\u201390, 91\u2013180 and &amp;gt;180\u2009days, respectively).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In a cohort of predominantly male veterans with CKD Stages 3 and 4, ACEI\/ARB discontinuation was independently associated with an increased risk of subsequent death and ESKD. This may be due to the severity of illness factors that drive the decision to discontinue therapy. Further investigations to determine the causes of discontinuations and to provide an evidence base for discontinuation decisions are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfaa300","type":"journal-article","created":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T15:20:17Z","timestamp":1604503217000},"page":"1893-1899","source":"Crossref","is-referenced-by-count":52,"title":["Renin\u2013angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0219-2870","authenticated-orcid":false,"given":"Carl P","family":"Walther","sequence":"first","affiliation":[{"name":"Department of Medicine, Section of Nephrology, Baylor College of Medicine, Selzman Institute for Kidney Health, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang C","family":"Winkelmayer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Nephrology, Baylor College of Medicine, Selzman Institute for Kidney Health, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A","family":"Richardson","sequence":"additional","affiliation":[{"name":"Health Policy, Quality & Informatics Program, Michael E. DeBakey VA Medical Center Health Services Research & Development Center for Innovations, Houston, TX, USA"},{"name":"Department of Medicine, Section of Health Services Research, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim S","family":"Virani","sequence":"additional","affiliation":[{"name":"Health Policy, Quality & Informatics Program, Michael E. DeBakey VA Medical Center Health Services Research & Development Center for Innovations, Houston, TX, USA"},{"name":"Department of Medicine, Section of Health Services Research, Baylor College of Medicine, Houston, TX, USA"},{"name":"Section of Cardiology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA"},{"name":"Department of Medicine, Section of Cardiovascular Research, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D","family":"Navaneethan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Section of Nephrology, Baylor College of Medicine, Selzman Institute for Kidney Health, Houston, TX, USA"},{"name":"Section of Nephrology, Michael E. DeBakey Veterans Affairs Medical Center, Houston, TX, USA"},{"name":"Institute of Clinical and Translational Research, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,12,25]]},"reference":[{"key":"2021120106122980700_gfaa300-B1","first-page":"1","article-title":"Kidney Disease: Improving Global Outcomes CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Levin","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"2021120106122980700_gfaa300-B2","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1681\/ASN.2006040356","article-title":"Renin-angiotensin-aldosterone system and progression of renal disease","volume":"17","author":"R\u00fcster","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"2021120106122980700_gfaa300-B3","year":"2014"},{"key":"2021120106122980700_gfaa300-B4","first-page":"e13","article-title":"2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"71","author":"Whelton","year":"2018","journal-title":"Hypertension"},{"key":"2021120106122980700_gfaa300-B5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MNH.0000000000000484","article-title":"Renin\u2013angiotensin system inhibition in advanced chronic kidney disease: how low can the kidney function go?","volume":"28","author":"Shah","year":"2019","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2021120106122980700_gfaa300-B6","year":"2017"},{"key":"2021120106122980700_gfaa300-B7","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.2215\/CJN.03830318","article-title":"Facility-level variations in kidney disease care among veterans with diabetes and CKD","volume":"13","author":"Navaneethan","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021120106122980700_gfaa300-B8","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.3109\/0886022X.2012.717478","article-title":"Major barriers against renin-angiotensin-aldosterone system blocker use in chronic kidney disease stages 3\u20135 in clinical practice: a safety concern?","volume":"34","author":"Yildirim","year":"2012","journal-title":"Ren Fail"},{"key":"2021120106122980700_gfaa300-B9","doi-asserted-by":"crossref","first-page":"e012674","DOI":"10.1136\/bmjopen-2016-012674","article-title":"What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis","volume":"7","author":"Whiting","year":"2017","journal-title":"BMJ Open"},{"key":"2021120106122980700_gfaa300-B10","doi-asserted-by":"crossref","first-page":"e012690","DOI":"10.1136\/bmjopen-2016-012690","article-title":"Prescription of renin\u2013angiotensin system blockers and risk of acute kidney injury: a population-based cohort study","volume":"6","author":"Mansfield","year":"2016","journal-title":"BMJ Open"},{"key":"2021120106122980700_gfaa300-B11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.2215\/CJN.14021118","article-title":"Stopping RAS inhibitors to minimize AKI: more harm than good?","volume":"14","author":"Tomson","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021120106122980700_gfaa300-B12","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2021120106122980700_gfaa300-B13","first-page":"312","article-title":"Association between intensity of statin therapy and mortality in persons with chronic kidney disease","volume":"35","author":"Walther","year":"2020","journal-title":"Nephrol Dial Transplant"},{"key":"2021120106122980700_gfaa300-B14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1053\/j.ajkd.2017.06.025","article-title":"Receipt of nephrology care and clinical outcomes among veterans with advanced CKD","volume":"70","author":"Fung","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2021120106122980700_gfaa300-B15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"2021120106122980700_gfaa300-B16","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"2021120106122980700_gfaa300-B17","doi-asserted-by":"crossref","first-page":"1065\u20131073.e3","DOI":"10.1016\/j.amjmed.2020.03.037","article-title":"Longer predialysis ACEi\/ARB utilization is associated with reduced postdialysis mortality","volume":"133","author":"Gosmanova","year":"2020","journal-title":"Am J Med"},{"key":"2021120106122980700_gfaa300-B18","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1681\/ASN.2004070597","article-title":"Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease","volume":"16","author":"Weiner","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2021120106122980700_gfaa300-B19","doi-asserted-by":"crossref","first-page":"e0135834","DOI":"10.1371\/journal.pone.0135834","article-title":"Validity of diagnostic codes for acute stroke in administrative databases: a systematic review","volume":"10","author":"McCormick","year":"2015","journal-title":"PLoS One"},{"key":"2021120106122980700_gfaa300-B20","first-page":"337","article-title":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"2","author":"Becker","year":"2012","journal-title":"Kidney Int Suppl"},{"key":"2021120106122980700_gfaa300-B21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1056\/NEJMoa053107","article-title":"Efficacy and safety of benazepril for advanced chronic renal insufficiency","volume":"354","author":"Hou","year":"2006","journal-title":"N Engl J Med"},{"key":"2021120106122980700_gfaa300-B22","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1097\/01.ASN.0000146423.71226.0C","article-title":"Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results","volume":"15","author":"Remuzzi","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2021120106122980700_gfaa300-B23","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1681\/ASN.V12122832","article-title":"ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy","volume":"12","author":"Ruggenenti","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"2021120106122980700_gfaa300-B24","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2021120106122980700_gfaa300-B25","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin-angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"2021120106122980700_gfaa300-B26","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1016\/j.mayocp.2019.05.031","article-title":"Discontinuation of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease","volume":"94","author":"Qiao","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2021120106122980700_gfaa300-B27","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1001\/jamainternmed.2020.0193","article-title":"Association between renin-angiotensin system blockade discontinuation and all-cause mortality among persons with low estimated glomerular filtration rate","volume":"180","author":"Qiao","year":"2020","journal-title":"JAMA Intern Med"},{"key":"2021120106122980700_gfaa300-B28","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.xkme.2019.12.007","article-title":"ACE inhibitor\/angiotensin receptor blocker use patterns in advanced CKD and risk of kidney failure and death","volume":"2","author":"Arora","year":"2020","journal-title":"Kidney Med"},{"key":"2021120106122980700_gfaa300-B29","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1681\/ASN.2018100971","article-title":"Trends in angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker use among those with impaired kidney function in the United States","volume":"30","author":"Murphy","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"2021120106122980700_gfaa300-B30","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jamainternmed.2018.4749","article-title":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with outcomes after acute kidney injury","volume":"178","author":"Brar","year":"2018","journal-title":"JAMA Intern Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/36\/10\/1893\/41323474\/gfaa300.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/36\/10\/1893\/41323474\/gfaa300.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T04:23:20Z","timestamp":1638332600000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/36\/10\/1893\/6048413"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,25]]},"references-count":30,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,12,25]]},"published-print":{"date-parts":[[2021,9,27]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfaa300","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.739274213.793581752","asserted-by":"object"}]},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,10,1]]},"published":{"date-parts":[[2020,12,25]]}}}